Sugi Predict

Sugi Predict / Compounds / SCHEMBL8198375

SCHEMBL8198375

SCHEMBL8198375

CC(C)NC[C@@H](N)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 1/20 0.50
▸ SLC1A3 P43003 5/20 0.45
▸ SLC1A2 P43004 5/20 0.45
▸ SLC1A1 P43005 4/20 0.45
▸ GFPT1 Q06210 1/20 0.43
▸ PTGS1 P23219 1/20 0.42
▸ SLC7A11 Q9UPY5 1/20 0.42
▸ GRIK1 P39086 5/20 0.39
▸ GRIA2 P42262 3/20 0.39
▸ GRIA4 P48058 3/20 0.39
▸ GRIK3 Q13003 3/20 0.39
▸ GRIK5 Q16478 3/20 0.39
▸ GRIK2 Q13002 3/20 0.39
▸ GRIA1 P42261 2/20 0.39
▸ GRM8 O00222 1/20 0.39
▸ GRM6 O15303 1/20 0.39
▸ GRIN2D O15399 1/20 0.39
▸ GRIN3B O60391 1/20 0.39
▸ GSR P00390 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8182619 1.00 SLC7A5 (0.50) SLC7A5SLC1A3SLC1A2SLC1A1GFPT1
SCHEMBL13673926 1.00 SLC7A5 (0.50) SLC7A5SLC1A3SLC1A2SLC1A1GFPT1
SCHEMBL25660460 0.84 SLC7A5 (0.48) SLC7A5SLC1A3SLC1A2SLC1A1GFPT1
SCHEMBL19091259 0.80 SLC1A3 (0.45) SLC7A5SLC1A3SLC1A2SLC1A1GFPT1
SCHEMBL17946723 0.79 ADRB2 (0.34) SLC7A5CYP1A2
SCHEMBL13673919 0.77 ADRB2 (0.39) —
SCHEMBL25406097 0.77 SLC1A3 (0.46) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
SCHEMBL20988097 0.77 SLC1A3 (0.47) SLC7A5SLC1A3SLC1A2SLC1A1GFPT1
SCHEMBL2236943 0.77 SLC1A3 (0.46) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1
SCHEMBL2236935 0.77 SLC1A3 (0.46) SLC7A5SLC1A3SLC1A2SLC1A1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240336654-A1 ANTIMICROBIAL PEPTIDOMIMETICS Universität Zürich (CH) 2024-10-10 — — US claimed
US-20240228555-A9 ANTIMICROBIAL PEPTIDOMIMETICS BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) 2024-07-11 — — US claimed
EP-4380689-A1 ANTIMICROBIAL PEPTIDOMIMETICS Basilea Pharmaceutica International AG, Allschwil (CH) 2024-06-12 — — EP claimed
CN-118043339-A Antimicrobial peptidomimetics 巴斯利尔药物阿尔施维尔国际股份公司 2024-05-14 — — CN claimed
US-20240132553-A1 ANTIMICROBIAL PEPTIDOMIMETICS SPEXIS AG (CH) 2024-04-25 — — US claimed
US-20240082346-A1 Composition Comprising an Antiviral Agent and a CXCR4 Selective Antagonist and Methods For Using the Same MAINLINE BIOSCIENCES (SHANGHAI) CO., LTD. (CN) 2024-03-14 — — US claimed
US-11771736-B2 Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same MAINLINE BIOSCIENCES (SHANGHAI) CO., LTD. (CN) 2023-10-03 — — US claimed
EP-4214220-A1 ANTIMICROBIAL PEPTIDOMIMETICS Spexis AG (CH) 2023-07-26 — — EP claimed
WO-2023012319-A1 ANTIMICROBIAL PEPTIDOMIMETICS SPEXIS AG (CH) 2023-02-09 — — WO claimed
WO-2022028737-A1 ANTIMICROBIAL PEPTIDOMIMETICS POLYPHOR AG (CH) 2022-02-10 — — WO claimed
US-20240336654-A1 ANTIMICROBIAL PEPTIDOMIMETICS Universität Zürich (CH) 2024-10-10 — — US disclosed
US-20240228555-A9 ANTIMICROBIAL PEPTIDOMIMETICS BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) 2024-07-11 — — US disclosed
CN-118043339-A Antimicrobial peptidomimetics 巴斯利尔药物阿尔施维尔国际股份公司 2024-05-14 — — CN disclosed
US-20240132553-A1 ANTIMICROBIAL PEPTIDOMIMETICS SPEXIS AG (CH) 2024-04-25 — — US disclosed
US-20240082346-A1 Composition Comprising an Antiviral Agent and a CXCR4 Selective Antagonist and Methods For Using the Same MAINLINE BIOSCIENCES (SHANGHAI) CO., LTD. (CN) 2024-03-14 — — US disclosed
US-20100016238-A1 Peptides for Use in the Treatment of Obesity NOVO NORDISK A/S (DK) 2010-01-21 — — US disclosed
US-20100016238-A1 Peptides for Use in the Treatment of Obesity NOVO NORDISK A/S (DK) 2010-01-21 — — US disclosed
US-20100016237-A1 Novel Peptides for Use in the Treatment of Obesity NOVO NORDISK A/S (DK) 2010-01-21 — — US disclosed
WO-2008087186-A2 PEPTIDES FOR USE IN THE TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2008-07-24 — — WO disclosed
WO-2008087187-A1 PEPTIDES FOR USE IN THE TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2008-07-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016238-A1 Peptides for Use in the Treatment of Obesity MC4R, GIPR, MC3R SLC7A5 1224/4885SLC1A3 895/4885SLC1A2 1510/4885
US-20100016237-A1 Novel Peptides for Use in the Treatment of Obesity MC4R, MC3R, GIPR SLC7A5 1025/4885SLC1A3 975/4885SLC1A2 1548/4885
US-11771736-B2 Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same CXCR4, CXCR3, CXCR1 SLC7A5 3211/4885SLC1A3 1933/4885SLC1A2 1973/4885
US-20240082346-A1 Composition Comprising an Antiviral Agent and a CXCR4 Selective Antagonist and Methods For Using the Same CXCR4, CXCR3, CXCR1 SLC7A5 3546/4885SLC1A3 1899/4885SLC1A2 1928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.